MNK - Mallinckrodt Public Limited Company

NYSE - NYSE Delayed Price. Currency in USD

Mallinckrodt Public Limited Company

3 Lotus Park
The Causeway
Staines-Upon-Thames TW18 3AG
United Kingdom
44 17 8463 6700
http://www.mallinckrodt.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees3,900

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark Christopher TrudeauPres, CEO & Director2.79MN/A1961
Mr. Matthew K. HarbaughExec. VP & CFO1.21MN/A1970
Dr. Frank ScholzExec. VP of Global Operations & Pres of Specialty Generics986.65kN/A1969
Mr. Hugh M. O'NeillExec. VP and Pres of Autoimmune & Rare Diseases1.09MN/A1963
Dr. Gary M. PhillipsExec. VP & Chief Strategy Officer1.23MN/A1966
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Corporate Governance

Mallinckrodt Public Limited Company’s ISS Governance QualityScore as of April 1, 2018 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder Rights: 2; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.